Marrow Whispers: How B-Cell Circuitry May Shape Acquired Aplastic Anemia and Why CD20 Depletion Is Being Reconsidered

Acquired Aplastic Anemia as a Failure of Immune Restraint Inside the Marrow

Acquired aplastic anemia is best understood as a collapse of hematopoiesis that follows an immune decision to treat stem and progenitor compartments as expendable. The marrow becomes hypocellular not because it forgets how to grow cells, but because hematopoietic stem and progenitor cells are pressured into apoptosis, senescence, or functional arrest by immune-derived signals. Cytotoxic effector programs—classically framed around activated T cells—create a cytokine and cytolytic environment that erodes stem-cell fitness over time. That environment is not only inflammatory but informational, because interferon-skewed signaling rewires antigen presentation, stress pathways, and metabolic constraints within the niche. The clinical signature—pancytopenia—therefore represents a systems failure that spans adaptive immunity, stromal support, endothelial integrity, and progenitor resilience. What makes the disorder scientifically instructive is that the immune system is not attacking a pathogen, but rewriting the definition of “self” within the marrow’s most regenerative cells.

The traditional model places T cells at the center, and it is correct as far as it goes, but it can be deceptively complete. The marrow is not a flat arena where one lymphocyte population acts and the rest merely witnesses, because antigen handling, costimulation, and cytokine persistence require cooperation. B cells are built to serve as antigen-presenting cells with unusually efficient antigen capture through the B-cell receptor, and that feature matters when the relevant antigens are scarce, tissue-bound, or intermittently displayed. Once B cells participate in presenting marrow-associated antigenic material to T cells, they can help stabilize autoreactive circuits that would otherwise burn out. In parallel, B cells can seed cytokine tone through IL-6–class signaling and can amplify effector polarization by shaping the quality of T-cell help. When marrow failure persists, it often does so because the immune network finds ways to keep itself convinced, not because a single cell type remains continuously hyperactive.

There is also a tolerance story embedded in B-cell biology that is easy to overlook when attention is fixed on cytotoxicity. Regulatory B-cell compartments, including IL-10–competent phenotypes, contribute to immune braking by dampening antigen-presenting intensity and restraining proinflammatory differentiation programs. When these regulatory compartments are numerically reduced or functionally muted, the immune system loses a layer of local “quieting” that is especially relevant in tissue niches like bone marrow. In that setting, antigen presentation becomes sharper, costimulation becomes more permissive, and autoreactive help signals become more durable. The marrow microenvironment then experiences not only immune attack but an altered probability landscape in which escape from autoimmunity becomes less likely. This is why a B-cell narrative in aplastic anemia is not a replacement for T-cell biology, but a way of explaining why T-cell dominance can persist.

Crucially, once B cells enter the pathophysiologic frame, the disease stops looking like a single immune axis and starts looking like a coupled oscillator system. Cellular “hotspots” in marrow—regions where lymphoid and myeloid elements cluster—can function as local engines of antigen exchange, cytokine reinforcement, and effector licensing. Within such structures, B cells can simultaneously present antigen, receive CD40-class help signals, and differentiate toward antibody-secreting fates that further bias immune injury. Autoantibodies, even when not definitively mapped to a single marrow antigen, can still participate by opsonizing targets, activating complement, or acting as immune complexes that stimulate Fc receptor pathways. The point is not to declare antibodies the sole cause, but to recognize that B-cell effector outputs can deepen and prolong the inflammatory logic of the disease. With that network view in place, the next mechanistic question becomes unavoidable: what intracellular programs keep B cells activated and useful to the autoreactive circuit.

The Immunobiology of B-Cell Activation That Can Sustain Marrow Failure

B-cell activation in acquired aplastic anemia can be framed as a convergence of three functions that normally protect the host: antigen presentation, inflammatory mediator production, and differentiation into antibody-secreting lineages. The B-cell receptor is not simply a recognition module but an internalization and sorting device that concentrates antigen into processing pathways and surfaces it to T cells with high efficiency. When BCR signaling is tonically heightened, B cells survive longer, present more antigen, and resist regulatory cues that would normally enforce peripheral tolerance. That survival advantage matters in a marrow environment where inflammatory cytokines can otherwise impose attrition on lymphocyte subsets. In practical terms, heightened BCR signaling increases the dwell time of potentially autoreactive B-cell clones within the niche. The longer those clones persist, the more opportunities exist for iterative T-cell priming and epitope spreading within the marrow context.

The CD40/CD40L axis then acts like a molecular handshake that converts T-cell activation into B-cell durability and functional escalation. CD40 engagement drives costimulatory molecule expression and promotes germinal-center–like differentiation programs even outside classical lymphoid organs. In immune-mediated marrow failure, that axis can become a feedback loop, because activated T cells provide help signals that fortify the very B-cell antigen presentation that sustains T-cell activation. The result is a cooperative system where neither arm needs to be maximally abnormal for pathology to continue, because each arm supplies what the other lacks. When inflammatory conditions elevate BAFF tone, B cells receive additional survival signaling that can rescue low-affinity or autoreactive clones that would otherwise be deleted or anergized. IL-6–class support further pushes differentiation and inflammatory persistence, effectively increasing the “gain” of the immune circuit. Once these signals are established, the marrow becomes less a site of hematopoiesis and more a site of immunologic rehearsal against hematopoietic targets.

A separate but equally important layer is the failure of immunoregulatory B-cell programs that normally impose friction on autoimmunity. IL-10–competent regulatory B cells can suppress excessive antigen presentation and can reshape T-cell polarization away from tissue-destructive phenotypes. When those populations are depleted, underdeveloped, or transcriptionally constrained, the immune system’s internal negotiations tilt toward attack rather than restraint. This matters because tolerance is not a single gatekeeper molecule, but an ecosystem of weak brakes that collectively prevent runaway amplification. In aplastic anemia, a small decrement in multiple brakes can produce a large functional shift toward sustained immune aggression. Put differently, the disorder may be less about a single “on” switch and more about the disappearance of enough “off” switches. That framing makes B-cell immunoregulation clinically interesting even when definitive autoantigens remain elusive.

A marrow-centric view also forces attention onto clonal structure and spatial context. When B-cell repertoires show signs of clonal expansion, it implies selection pressure—an antigenic or microenvironmental advantage—that favors certain B-cell lineages. Even without asserting a single marrow antigen, clonal patterns suggest that the B-cell compartment is behaving as though it is responding to a persistent stimulus rather than transient inflammation. Spatially, immune clusters can facilitate repeated antigen encounters and can stabilize costimulatory contacts, making the immune response harder to extinguish. The marrow niche, with its stromal and endothelial signals, can also bias immune cells toward retention and survival, creating a physical substrate for immune persistence. This is one reason acquired aplastic anemia can appear clinically “stuck” once established, even when broad immunosuppression calms overt inflammation. At that point, the clinical challenge shifts toward identifying which patient subgroups are more likely to be driven by B-cell–dominant contributions rather than purely cytotoxic T-cell dominance.

Age and sex become particularly relevant because they tune the immune system’s baseline architecture before disease ever begins. Pediatric immune systems are still calibrating peripheral tolerance, memory formation, and regulatory compartment stability, which can make autoimmune patterns look immunophenotypically distinct even when symptoms converge. Female immune biology is shaped by hormone-responsive programs that influence B-cell survival, class-switch propensity, and antibody-related selection thresholds. These forces can plausibly modulate the balance between effector B-cell activation and regulatory B-cell restraint, shifting how the disease is expressed and how it responds to immunomodulation. Importantly, such differences do not require a different disease, only a different immune starting point and a different set of constraints on recovery. For that reason, the next mechanistic step is to examine how pediatric and female contexts could reweight B-cell pathways in ways that matter to therapy.

Pediatric and Female Immunophenotypes That Make B-Cell Targeting Tempting and Complicated

In pediatric acquired aplastic anemia, immune immaturity is not a vague concept but a measurable difference in subset composition, differentiation trajectories, and regulatory robustness. Transitional and regulatory B-cell populations can be developmentally variable, and that variability can influence how quickly tolerance is reasserted after an autoimmune trigger. Pediatric B cells may also exhibit activation-marker patterns that reflect heightened antigen-presenting readiness, which can amplify T-cell priming in a marrow environment already biased toward inflammatory signaling. When that occurs, the immune system can generate an adult-like capacity for tissue damage without an adult-like capacity for regulation and shutdown. The marrow then experiences a mismatch between effector competence and regulatory sophistication. Clinically, this helps explain why pediatric cases can be severe yet still exhibit immune plasticity when the correct immunomodulatory levers are applied.

A second pediatric layer involves transcriptional and metabolic programming that shapes what B cells can become. Differentiation regulators that normally support controlled effector maturation and regulatory lineage stability can be perturbed under inflammatory pressure. If regulatory differentiation programs are blunted, IL-10–competent restraint becomes harder to sustain exactly when it is most needed. Meanwhile, altered cellular energetics can bias immune cells toward activation states that are durable and less sensitive to inhibitory cues. In the marrow, where oxygen tension and nutrient availability already differ from peripheral blood, such metabolic biases can be amplified. This is not merely academic, because it changes how one should think about therapeutic timing: early intervention may redirect trajectories that later become entrenched. It also raises a practical question about B-cell depletion in children, because immune reconstitution is rapid and can restore the same dysregulated patterns if the underlying drivers are not addressed.

Female immunobiology introduces a different set of constraints, centered on hormone-responsive tuning of B-cell survival and autoreactivity thresholds. Estrogen-linked signaling can enhance B-cell persistence and can support antibody-associated differentiation programs, which may increase the probability that autoreactive clones remain in circulation or within niches. In marrow failure syndromes, that can translate into a higher likelihood of B-cell participation in sustaining antigen presentation and inflammatory feedback. At the same time, female immune systems often demonstrate strong humoral responsiveness, which can be protective against infection but destabilizing when tolerance is challenged. The key mechanistic point is that sex hormones can shift the equilibrium between deletion, anergy, and survival for autoreactive B cells. When that equilibrium shifts, the disease may appear more immunologically “sticky,” meaning it resists spontaneous resolution once triggered. That possibility makes B-cell targeting conceptually attractive, while also demanding careful monitoring for downstream immune consequences.

These subgroup considerations feed directly into interest in rituximab, but they also warn against oversimplification. Rituximab depletes CD20-positive B cells, which changes antigen presentation capacity and reduces the pool from which antibody-secreting lineages are replenished. Yet CD20 is not expressed on plasma cells, and it is not a universal marker of every pathogenic B-cell state, so depletion is substantial but not absolute. Moreover, if B-cell dysregulation in aplastic anemia is partly a response to T-cell–driven inflammation, then B-cell depletion alone may not extinguish the upstream inflammatory logic. This is why rituximab remains exploratory in acquired aplastic anemia rather than a standard therapeutic backbone. The drug is mechanistically coherent, but the disease’s causal hierarchy can vary across patients and across phases of illness.

Safety and subgroup context also matter because B-cell depletion changes the immune system’s relationship with viruses, vaccine responses, and immunoglobulin maintenance. Pediatric patients are still building durable humoral memory, so depletion can have developmental consequences that need to be weighed against potential benefit. Female patients may face additional considerations around reproductive planning, infection risk under combined immunosuppression, and the timing of vaccination relative to B-cell reconstitution. In both groups, the clinically relevant endpoint is not merely depletion, but the shape of immune reconstitution that follows depletion. If reconstitution preferentially restores activated, poorly regulated subsets, the long-term benefit may be limited despite short-term improvement. Conversely, if reconstitution restores regulatory balance, depletion can function as an immune “reset” rather than a temporary pause. This brings the narrative to its therapeutic core: what CD20 depletion actually does mechanistically, and why clinicians keep revisiting it despite guideline conservatism.

Rituximab as a Mechanistic Probe and an Off-Label Therapeutic Hypothesis

Rituximab’s pharmacology is often summarized as “B-cell depletion,” but the mechanistic reality is more precise and therefore more clinically useful. By binding CD20 on mature B cells, rituximab flags those cells for immune-mediated elimination through complement activation and Fc receptor–dependent effector pathways. That elimination reduces antigen presentation bandwidth, shrinks the pool of B cells capable of receiving T-cell help, and can dampen cytokine contributions that reinforce inflammatory circuits. It can also alter the architecture of lymphoid-like immune interactions by removing a major participant in costimulatory contact networks. In diseases where autoantibodies are dominant, rituximab can reduce future antibody production by eliminating precursors, even if existing plasma cells persist. In acquired aplastic anemia, the appeal is not guaranteed antibody causality, but the possibility that removing B-cell support destabilizes the autoreactive network enough for hematopoiesis to recover.

The exploratory role of rituximab in acquired aplastic anemia is best interpreted as a test of whether a given patient’s disease is partially B-cell–sustained rather than purely T-cell–driven. In practice, clinicians have considered rituximab in refractory settings, in overlap phenotypes where autoimmunity is conspicuous, or in contexts suggesting humoral contribution to cytopenias. The mechanistic rationale also extends to immune recalibration, because B-cell depletion can indirectly reshape T-cell activation states by reducing antigen presentation and altering cytokine tone. However, this logic must coexist with the reality that standard management strategies focus on immunosuppressive therapy and transplantation pathways that have stronger consensus support. Rituximab therefore sits in a narrow clinical space where mechanistic plausibility outpaces definitive evidence. That gap is not a failure of imagination, but a reflection of how difficult it is to prove B-cell causality in a disease dominated by marrow niche complexity and heterogeneous immune trajectories.

Pediatric and female considerations sharpen both the promise and the caution. In children, rituximab may function as an immune circuit interrupter when B-cell activation is visibly contributing to immune persistence, but depletion occurs in a developing immune system that must still establish long-lived protective memory. In female patients, B-cell depletion may counteract survival advantages of autoreactive clones that are supported by hormone-tuned programs, but the same intervention can produce prolonged susceptibility to certain infections and blunted vaccine responsiveness. In both subgroups, the most important mechanistic endpoint is not simply CD20 clearance, but whether regulatory compartments re-emerge in a way that restores immune tolerance to hematopoietic targets. That demands longitudinal immune monitoring—immunoglobulins, reconstitution kinetics, and functional immune competence—rather than reliance on short-term blood count shifts alone. It also encourages a more sophisticated therapeutic posture: rituximab as part of a strategy to reshape immune topology, not as a one-step cure.

Guideline frameworks reinforce this cautious posture by prioritizing established approaches while leaving rituximab in an exploratory category. Adult guidelines emphasize diagnostic rigor, risk stratification, transplantation eligibility, and conventional immunosuppression pathways rather than routine B-cell depletion. Pediatric consensus pathways similarly prioritize donor-based strategies and standard immunosuppression approaches, reflecting the balance between efficacy and the long-term immune costs of additional off-label agents. Broader consensus recommendations focus on structured decision-making for initial therapy, supportive care, and subsequent management rather than embracing rituximab as a standard option. This conservatism is not an indictment of B-cell biology, but a reminder that biological plausibility must be translated into predictable clinical benefit before it becomes routine. The scientific opportunity, therefore, is not to force rituximab into existing algorithms, but to define which immune signatures predict that B-cell modulation will meaningfully change marrow fate.

From a research standpoint, the field now needs a cleaner bridge between mechanistic markers and therapeutic selection. If activated B-cell phenotypes, reduced regulatory B-cell function, or spatial immune clustering patterns can be reliably tied to clinical trajectories, then CD20 depletion becomes testable as a precision intervention rather than a salvage improvisation. Trials must be designed to capture immune reconstitution as a primary story, because relapse risk may be determined by the quality of post-depletion immune rebuilding rather than the depth of initial depletion. Subgroup-aware designs are essential, because pediatric and female immunobiology can shift both baseline immune architecture and recovery kinetics. The most useful near-term outcome would be a validated set of immune measurements that identify when B cells are structural supports of the disease network. With that, rituximab can be repositioned from an exploratory idea to a mechanistically selected tool, and the therapeutic conversation can move naturally toward next-generation B-cell pathway modulation.

Study DOI: https://doi.org/10.3389/fimmu.2026.1737771

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph.,B.Sc. CompE

Editor-in-Chief, PharmaFEATURES